HTR2A and COVID-19: Thus, early treatment of COVID-19 patients with inhibitors targeting 5-HT2 and 5-HT3 receptors could potentially reduce the pathogenic effects of excessive serotonin levels, including thrombosis and thrombotic complications, potentially preventing progression to severe disease [42,44].